Red Light Holland and PharmAla to collaborate on medical psilocybin

Red Light Holland (CSE:TRIP) has entered into a collaboration with PharmAla Biotech Holdings (CSE:MDMA) for medical psilocybin.

Numinus Wellness offers turnkey exposure to psychedelic medicine

Stock investors searching for holistic exposure to psychedelic medicine should add Numinus Wellness to their due diligence lists.
PharmAla Biotech - PharmAla's LaNeo MDMA capsules.

PharmAla approved to sell MDMA and psilocybin in Canada

Health Canada has cleared PharmAla Biotech (CSE:MDMA) to sell MDMA and psilocybin to anyone legally permitted to hold them.

Clearmind posts results from weight loss pre-clinical trial

Clearmind Medicine (CSE:CMND) has revealed positive results from its weight loss pre-clinical trial in animal subjects.

Optimi Health completes psilocybin extract validation

Optimi Health (CSE:OPTI) has reached a significant milestone, the successful harvest of eight new natural psilocybin genetics.

First trial to assess real-world efficacy of MDMA in treating PTSD

PharmAla Biotech (CSE:MDMA) will start an observational trial on patients treated with 3,4 Methylenedioxymethamphetamine (MDMA).

PharmAla makes first MDMA and psilocybin shipment to Cortexa

PharmAla Biotech Holdings has completed its first shipment of MDMA and psilocybin to Cortexa, its joint venture with Vitura Health Ltd.

Legal cocaine stock hires cannabis and psychedelics pioneer

Safe Supply Streaming (CSE:SPLY), a stock investing in legal cocaine, has appointed Ronan Levy as president.

Global healthcare leader acquires microcap psychedelic stock

Otsuka Pharmaceutical has acquired Mindset Pharma, a microcap psychedelic stock developing drugs for psychiatric and neurological disorders.

Cybin gears up to acquire Small Pharma Inc.

Cybin (NEO:CYBN) is gearing up to acquire Small Pharma Inc. (TSXV:DMT) to create the psychedelics industry's largest DMT program.

World’s first psychedelic microdosing home trials ready for Phase 2

MindBio Therapeutics (CSE:MBIO) received the first batch of its drug for take-home use in Phase 2 psychedelic microdosing clinical trials.

The biotech/pharma team set up to enhance psychedelic therapeutics

Clearmind Medicine (CSE:CMND) has agreed to collaborate on product development with pharmaceutical and consumer products company CTS Ltd.

Red Light Holland starts stability testing for psilocybin capsules

Red Light Holland (CSE:TRIP) begins stability testing for its psilocybin microdosing capsules The capsules were developed...

Optimi Health to supply MDMA for therapist experiential training program

Optimi Health (OPTI) will manufacture and supply MDMA for the program set to take place later...

Psychedelics stock’s LSD clinical trial reports sleep quality breakthrough

Psychedelics stock MindBio Therapeutics (CSE:MBIO) made a major discovery from sleep data from its LSD-microdosing trials...

Psychedelics company begins phase 3 psilocybin study for depression

Psychedelics company Numinus Wellness has initiated a study on COMP360 psilocybin for treatment-resistant depression (TRD) as...